Ispire Technology (ISPR) risk factors, FY2024 10-K

Ispire Technology's FY2024 10-K, filed Sep 27, 2024, lists 45 risk factors in 2 groups. There is no earlier 10-K to compare against, so the most company-specific risks are listed below.

Risk factors listed
452 groups
Section length
17k wordsItem 1A

Ispire Technology's biggest risks in the FY2024 10-K

  • Ispire faces heavy losses, with a net loss of $14.8 million for the fiscal year ended June 30, 2024.
  • Operations rely heavily on related party Shenzhen Yi Jia for manufacturing and a single distributor generating up to 32.4% of revenue.
  • The company is exposed to intense regulatory scrutiny in the nicotine and cannabis vaping markets.

The risks most specific to Ispire Technology

  • Risks Related to Our Business and Industry

    We sustained losses of approximately $6.0 million for the year ended June 30, 2023 (as restated) and $14.8 million for the year ended June 30, 2024, and we cannot assure you that we can or will operate profitably in the future

    We sustained net losses of $6.0 million and $14.8 million for the fiscal years ended June 30, 2023, and June 30, 2024, respectively.

  • Risks Related to Our Business and Industry

    We are exposed to risks relating to our relationship with a related party, and we may not be able to successfully operate manufacturing operations

    The majority of our products are manufactured by related party Shenzhen Yi Jia, creating operational and business interruption risks.

  • Risks Related to Our Business and Industry

    One customer accounts for a significant portion of our sales

    Our largest non-exclusive distributor accounted for approximately 32.4% and 30.0% of our revenue for fiscal years 2023 and 2024, respectively.

  • Risks Related to Our Business and Industry

    Our failure to collect accounts receivable from our customers may adversely affect the results of our operations

    We recorded an allowance for credit losses of approximately $1.5 million for fiscal 2023 and $5.9 million for fiscal 2024 due to collection issues.

  • Risks Related to Our Business and Industry

    Our need to restate our unaudited financial statements reflected a material weakness in our internal controls over financial reporting

    We had to restate our unaudited financial statements for periods in fiscal 2023 due to a material weakness in internal controls over financial reporting.

  • Risks Related to Our Business and Industry

    Because we are a “controlled company” as defined in the Nasdaq Stock Market Rules, you may not have protection of certain corporate governance requirements which otherwise are required by Nasdaq’s rules

    We are a controlled company under Nasdaq rules because co-CEO Mr. Tuanfang Liu holds more than 50% of our voting power.

All 45 risk factors

Headings as the filing states them, in filing order.

Risks Related to Our Business and Industry

  1. 01We sustained losses of approximately $6.0 million for the year ended June 30, 2023 (as restated) and $14.8 million for the year ended June 30, 2024, and we cannot assure you that we can or will operate profitably in the future
  2. 02Existing laws, regulations and policies and the issuance of new or more stringent laws, regulations, policies and any other restrictions or limitations in relation to the nicotine vaping industry have and can materially and adversely affect our business operations
  3. 03Cannabis vapor products are subject to regulations and restrictions in the United States and are prohibited in many other countries
  4. 04While we believe that our business and sales do not violate the Federal Paraphernalia Law, legal proceedings alleging violations of such law or changes in such law or interpretations thereof could adversely affect our business, financial condition or results of operations
  5. 05The recent implementation of regulations relating to e-cigarettes has resulted in our decision not to market nicotine products in the United States until we secure PMTA approvals on our ENDS devices
  6. 06Recently enacted legislation and regulations in the United States may make it more difficult to sell nicotine and cannabis vaping products in the United States
  7. 07We are exposed to risks relating to our relationship with a related party, and we may not be able to successfully operate manufacturing operations
  8. 08If it is determined or perceived that the usage of nicotine or cannabis vaping products poses long-term health risks, the use of vaping products may decline significantly, which is likely to materially and adversely affect our business, financial condition, and results of operations
  9. 09If vaping product usage is determined or perceived to pose long-term health risks or to be linked to illnesses, the usage of vaping products may significantly decline, which would have a material adverse effect on our business, financial condition and results of operations
  10. 10Because cannabis oil, unlike nicotine oil, is not of a uniform quality, products we design may not perform as intended, which could result in a loss of business
  11. 11The vaping market may develop more slowly or differently than we expect
  12. 12We are exposed to product liability and user complaints arising from the products we sell, which could have a material adverse impact on us
  13. 13Further, although we may have legal recourse against Shenzhen Yi Jia pursuant to applicable laws, attempts to enforce our rights against Shenzhen Yi Jia may be expensive, time-consuming and may not be successful, particularly since Shenzhen Yi Jia is located in China, and we may not be able prevail in a Chinese court
  14. 14Our business, financial condition and results of operations may be adversely impacted by product defects or other quality issues
  15. 15Our business and the industry in which we operate are subject to inherent risks and uncertainties, including, among others, developments in regulatory landscape, medical discovery and market acceptance of vaping devices
  16. 16We may not be able to develop and introduce new products or upgrade existing products in a timely and cost-effective manner, which may adversely affect our business, results of operations and prospects
  17. 17Misuse or abuse of our products may lead to potential adverse health effects, subjecting us to complaints, product liability claims and negative publicity
  18. 18Failure to manage inventory at optimal levels could adversely affect our business, financial condition, and results of operations
  19. 19One customer accounts for a significant portion of our sales
  20. 20We face competition from companies in the vaping industry as well as other sources of nicotine and cannabis, and we may fail to compete effectively
  21. 21Misconduct, including illegal, fraudulent or collusive activities, by our employees, distributors, retailers, suppliers and manufacturers, may harm our brand and reputation and adversely affect our business and results of operations
  22. 22We may become subject to governmental regulations and other legal obligations related to privacy, information security, and data protection, and any security breaches, and our actual or perceived failure to comply with our legal obligations could harm our brand and business
  23. 23We may be subject to liability if private information that we receive is not secure or if we violate privacy laws and regulations
  24. 24Any significant cybersecurity incident or disruption of our information technology systems or those of third-party partners could materially damage user relationships and subject us to significant reputational, financial, legal and operation consequences
  25. 25Infringement of our intellectual property by any third party or loss of our intellectual property rights may materially and adversely affect our business, financial condition and results of operations
  26. 26We may be subject to intellectual property infringement claims from third parties, which may be expensive to defend with no assurance of success and may disrupt our business and operations
  27. 27As the patents we own or are licensed to us may expire and may not be extended, our patent applications may not be granted and our patent rights may be contested, circumvented, invalidated or limited in scope, our patent rights and license may not protect us
  28. 28If we are unable to manage our growth or execute our strategies effectively, our business and prospects may be materially and adversely affected
  29. 29Our success depends on our ability to retain our core management team and other key personnel
  30. 30Competition for highly skilled employees is intense, and we may not be able to attract and retain the highly skilled employees needed to support our business
  31. 31Our business, financial condition and results of operations may be adversely affected by an economic downturn
  32. 32Our need to restate our unaudited financial statements reflected a material weakness in our internal controls over financial reporting
  33. 33As a result of our restatement of our unaudited financial statements as described in the preceding risk factor, our internal controls over financial reporting were not effective, which could have a significant and adverse effect on our business and reputation
  34. 34Although we believe that our business is not subject to PRC Laws, our business could be materially impaired if it is determined that our business is subject to PRC Laws
  35. 35We have limited insurance coverage, which could expose us to significant costs and business disruption
  36. 36The occurrence of natural disasters may adversely affect our business, financial condition and results of operations
  37. 37Because we are a “controlled company” as defined in the Nasdaq Stock Market Rules, you may not have protection of certain corporate governance requirements which otherwise are required by Nasdaq’s rules
  38. 38You may experience difficulties in effecting service of legal process, enforcing foreign judgments or bringing actions in China against two of our directors, Tuanfang Liu, our co-chief executive officer and chairman, and his wife Jiangyan Zhu, who are both based in China
  39. 39Our failure to collect accounts receivable from our customers may adversely affect the results of our operations

Risks Related to Our Common Stock

  1. 40Our failure to meet the continued listing requirements of Nasdaq could result in a delisting of our Common Stock
  2. 41If our shares are delisted from Nasdaq and become subject to the penny stock rules, it would become more difficult to trade our shares
  3. 42The trading price of our Common Stock may be volatile, which could result in substantial losses to investors
  4. 43As an “emerging growth company” under the Jumpstart Our Business Startups Act, or JOBS Act, we are permitted to, and intend to, rely on exemptions from certain disclosure requirements
  5. 44If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, the market price for our Common Stock and trading volume could decline
  6. 45Our by-laws include forum selection provisions which may limit your ability to commence an action against us

Other Ispire Technology 10-Ks

  • FY2026 10-K risk factors
    51 risks7 new1 dropped2 reworded

    Seven new risks center on pre-revenue joint ventures, FDA approval of IKE technology, cash needs, and potential loss of invested capital.

    Filed Sep 15, 2026
  • FY2025 10-K risk factors
    45 risks2 new2 dropped4 reworded

    The company added specific risks regarding tariffs on imports from China and Malaysia and customer credit risks in the cannabis sector. Net losses widened significantly to $39.2 million for the year ended June 30, 2025. Allowance for credit losses increased sharply to $18.0 million.

    Filed Sep 15, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.